TransMedics Group Inc vs Tyson Foods, Inc. — how do they compare? TransMedics Group Inc trades at $87.58 (market cap $3.10B), while Tyson Foods, Inc. trades at $56.59 (market cap $19.85B). The key difference: Tyson Foods, Inc. is far larger — about 6.4× TransMedics Group Inc's market cap, and Tyson Foods, Inc. pays a 3.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | TSN | |
|---|---|---|
Market Cap | $3.10B | $19.85B |
Sector | Technology | Consumer Staples |
52-Week High | $150.42 | $68.75 |
52-Week Low | $61.99 | $50.72 |
Enterprise Value | $3.49B | $27.12B |
Dividend Yield | — | 3.62% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Tyson Foods (TSN) trades at $55.97, down 2.08% on the day, amid a bearish technical signal and mixed quarterly performance. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue and volumes declined year-over-year. The company maintains a strong cash flow from operations of $2.16B in 2025, though net income margins are thin at 1.03%. Analyst consensus is a Buy with a $68.50 price target, highlighting a potential 22% upside from current levels.
The outlook for TSN is cautiously optimistic, with valuation metrics like P/S of 0.36 and EV/EBITDA of 10.38 suggesting potential undervaluation. Key risks include persistent losses in the beef segment due to high cattle costs and competitive pressures. Investment opportunity lies in the strength of chicken and prepared foods divisions, supported by a stable dividend yield. Monitoring Q3 2026 earnings release and beef margin normalization is critical for future performance.
Trailing returns across standard periods
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →